Clinical Trial Search

Primary: Alzheimer's Disease Assessment Scale - Cognition (ADAS-COG11, Modified Version) Score — 20.6; 19.2; 30.2; 25.3 score on a scale — p=<0.05

Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months

Primary: Mean Level of HIV-1 RNA in Plasma of Participants While on Acyclovir or Valacyclovir. — 3.56; 2.94 log10 copies/mL

Primary: Percent of Participants With Regimen Failure, Defined as a Confirmed Virologic Failure or Discontinuation of Randomized NRTI Component of Study Treatment — 26.0; 29.8…

Primary: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 — 5.004; 4.923; 4.866; 4.636 log10 c/mL

Primary: Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis) — 95; 110 participants — p=<0.05

Primary: Change in Levels of CD8+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+) From Baseline to Weeks 24 and 48 on ART — -4.01 % of CD8+ T-cells — p=0.001

Primary: Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs — 168; 110; 51; 10 participants

Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells

Primary: HIV Viral Load < 400 Copies/ml — 40; 50 percentage of participants

Primary: Treatment Response at Week 48 — 126; 124; 250; 126 Patients — p=0.684

Primary: Time From Randomization to Virologic Failure — 36; 24; 24; 24 Weeks

Primary: Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo…

Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio

Primary: Cumulative Probability of First Virologic Failure by Week 96 — 13; 10; 15 cumulative probability per 100 persons

Primary: Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation — -0.53; 0.03 log10 copies/mL

Primary: Substudies 01, 02 and 03: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical…

Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants

Primary: Confirmed Virologic Failure at or Prior to Week 48 — 95; 105; 34; 23 participants — p=0.133

Primary: Change in Standardized Uptake Value Ratio (SUVR) of (18F-Florbetapir PET) From Week 0 to Week 52. — 0.07; 0.08 Standardized Uptake Value Ratio

Primary: Total HIV DNA From CD4 T-cells — 2.95; 3.06 HIV-DNA copies/mill CD4+ T cells (log10) — p=0.26

Primary: Summary of Change From Baseline in Alanine Aminotransferase (ALT) to Last Value on Treatment — 1.0 IU/L

Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml

Primary: Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms…

Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 56 — 0.18; 0.42 copies/mL on log scale

Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants

Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants

Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr

Primary: Flow-mediated Dilation of the Brachial Artery — 2.25; 3.36 percent dilation of the brachial artery — p=0.52

Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 — 0.30; 0.00; 0.18; 0.04 copies/mL on log scale